Status:
COMPLETED
Renal Involvement in Hospitalized Children With COVID-19
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Acute Kidney Injury
Covid19
Eligibility:
All Genders
1-14 years
Brief Summary
Covid-19 is an important human and animal pathogen, it mostly causes respiratory and gastrointestinal symptoms. Clinical features range from a common cold to severe diseases such as severe acute respi...
Detailed Description
COVID-19 usually causes respiratory and gastrointestinal symptoms, Clinical features range from a common cold to severe diseases such as bronchitis, pneumonia, severe acute respiratory distress syndro...
Eligibility Criteria
Inclusion
- All pediatric patients with COVID-19 were admitted to Hamad Hospital from (0 to 14) years, using the electronic medical records (Cerner), over that time period (from March 1, to January 1, 2021), with one of the following:
- Proteinuria: (≥1+) on dipstick analysis.
- Hematuria: ≥ 5 RBC/HPF.
- Sterile Pyuria: ≥ 5 WBC/HPF or ≥10 WBC/mm3 with negative urine culture (44).
- Hypernatremia :\> 145meq/l.
- Hyponatremia: \< 135 meq/l.
- Hypokalemia :\< 3.5meq/l.
- Metabolic acidosis (ph \<7.35).
- Elevated serum creatinine :\> upper limit of reference interval (ULRI) values.
- Elevated serum urea: \> 7 mmol/l.
- Urine specific gravity (SG) \<1.003.
Exclusion
- \* Patient with previous chronic kidney diseases.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04788394
Start Date
March 1 2021
End Date
December 31 2021
Last Update
July 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad General corporation
Doha, Qatar, 3050